The biotechnology industry has seen transformative M&A over the past three years — Amgen's $28 billion Horizon Therapeutics acquisition, CSL's $11.7 billion Vifor Pharma acquisition, and numerous platform technology and pipeline asset acquisitions. The patent cliff facing blockbuster biologics is driving acquisition of late-stage pipeline assets and platform technologies. This report covers every significant biotechnology transaction over the past three years with analysis of strategic rationale, valuation multiples, and competitive implications.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Table of Contents
1. Executive Summary
2. Overview
3. Oncology M&A
4. Immunology M&A
5. Rare Disease M&A
6. Gene Therapy M&A
7. Financial Analysis
8. Strategic Rationale
9. Integration Outcomes
10. Outlook 2026-2028
11. Competitive Landscape
12. Strategic Conclusions
13. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
